FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 12:21:55 23/05/2024 BST | ||
| 3.84 EUR / 3.86 EUR | -15.20% |
|
| Current month | -45.30% | ||
| 1 month | -55.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 3.83 | -15.64% |
| 22/05/24 | 4.54 | -9.92% |
| 21/05/24 | 5.04 | +2.65% |
| 20/05/24 | 4.91 | -11.21% |
| 17/05/24 | 5.53 | +10.82% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 09:24 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1SF5 |
| ISIN | DE000MG1SF58 |
| Date issued | 05/04/2024 |
| Strike | 1,043 kr |
| Maturity | Unlimited |
| Parity | 3.56 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.72 € |
|---|---|
| Lowest since issue | 3.83 € |
| Spread | 0.02 € |
| Spread % | 0.51% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- Certificat
